RxDoctor Payments Data

Carmen Duncan, NP

Family · Valdosta, GANPI 1659154011

Payments from drug & device makers

$4,004in general payments, 2019–2025

Across 177 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$432
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$317
  • Ardelyx, Inc.$269
  • Sanofi$257
  • Braintree Laboratories, Inc.$173
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,90097%
  • Education$1043%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,004 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$28,500
Medicare patients
241
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase34$99,073
LinzessLinaclotide96$72,667
IbsrelaTenapanor Hcl24$40,920
Sucralfate126$17,595
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C115$16,315
Lubiprostone104$10,492
Dexlansoprazole DrDexlansoprazole29$6,726
Colesevelam Hcl103$6,477
Mesalamine22$5,165
Pantoprazole Sodium565$5,074
Famotidine418$5,074
Esomeprazole Magnesium97$2,770
Omeprazole253$2,525
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,780
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl95$1,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,470$171,740130 claims
Ardelyx, Inc.Ibsrela$269$40,92024 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$317$16,315115 claims
Braintree Laboratories, Inc.Sutab$173$1,78011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →